跳至主要内容
临床试验/CTRI/2023/12/060727
CTRI/2023/12/060727尚未招募Unknown

Comparative Evaluation of Levels of Salivary Visfatin and Aspartate Aminotransferase in Stage-II and Stage-III Periodontitis treated by Phase I Periodontal Therapy - A Prospective Clinical Study.

Dr Vivek Kanjibhai Bhesaniya1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年1月2日最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
Levels of Salivary Visfatin and

研究概览

简要总结

Periodontitis is one of the most prevalent oral diseases in the world. Approximately 5–20% of adults worldwide suffer from severe periodontitis which may lead to tooth loss. Biomarkers found in saliva can be evaluated to check for disease activity. Visfatin is a pre-B cell colony enhancing factor, a newly discovered adipokine released from adipose tissue, macrophages, and leukocytes. Aspartate aminotransferase  (AST) is an enzyme that can be found in cells all over the body and there is a direct relation between AST level and quantity of tissue impairment. This biomarker will provides a safe, and non-invasive approach for periodontal disease detection, and possesses a high potential to revolutionize the next generation of diagnostics. Thus  , the aim of this study was to evaluate the role of visfatin and Aspartate aminotransferase as best reliable diagnostic and prognostic biomarkers in oral diseases like periodontitis .

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Male and female patients of age groups 18 to 70 years.
  • Minimum 20 teeth should be present.
  • Patient diagnosed as Stage-II or Stage-III periodontitis.
  • Systemically healthy patients.
  • Patients ready to comply fully and willing to give consent form the final evaluation.
  • Patients having ability to maintain optimum oral hygiene.

排除标准

  • Patients with systemic diseases.
  • Smoking and alcoholism
  • Teeth no less than
  • Patients on antibiotics and anti-inflammatory drugs since 6 months.
  • Pregnant or lactating females.
  • Patients undergoing orthodontic treatment.
  • Those who have undergone periodontal surgical treatment with in the last 6 months
  • Patient with obesity (BMI- more or equal to 30).

结局指标

主要结局

Levels of Salivary Visfatin and

时间窗: 1st measurement at baseline and 2nd measurement at 4 weeks after Phase - I Periodontal therapy

Aspartate Aminotransferase

时间窗: 1st measurement at baseline and 2nd measurement at 4 weeks after Phase - I Periodontal therapy

次要结局

  • 1) Probing pocket depth(2) Clinical attachment level)

研究者

发起方
Dr Vivek Kanjibhai Bhesaniya
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验